FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development.
James M ByrneUrsula WaackEdward A WeinsteinAbhay JoshiSimone M ShurlandDmitri IarikovJuergen B BulittaBinh An DiepTina GuinaWilliam W HopeMatthew B LawrenzAlexander J LepakBrian M LunaLynn MieselAndrew J PhippsThomas J WalshWilliam WeissThushi AminiJohn J FarleyPublished in: Antimicrobial agents and chemotherapy (2020)
The U.S. Food and Drug Administration (FDA) hosted a public workshop entitled "Advancing Animal Models for Antibacterial Drug Development" on 5 March 2020. The workshop mainly focused on models of pneumonia caused by Pseudomonas aeruginosa and Acinetobacter baumannii The program included discussions from academic investigators, industry, and U.S. government scientists. The potential use of mouse, rabbit, and pig models for antibacterial drug development was presented and discussed.
Keyphrases
- acinetobacter baumannii
- pseudomonas aeruginosa
- drug administration
- silver nanoparticles
- multidrug resistant
- drug resistant
- healthcare
- cystic fibrosis
- mental health
- biofilm formation
- essential oil
- human health
- anti inflammatory
- quality improvement
- wound healing
- staphylococcus aureus
- risk assessment
- medical students
- community acquired pneumonia
- mechanical ventilation